FibroGen Reports First Quarter 2017 Financial Results
May 09, 2017 16:02 ET
|
FibroGen, Inc.
SAN FRANCISCO, May 09, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today reported financial results for the first quarter of 2017 and provided...
FibroGen Reports Fiscal 2016 Financial Results
March 01, 2017 16:02 ET
|
FibroGen, Inc.
SAN FRANCISCO, March 01, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today reported financial results for the year ended December 31, 2016, and...
FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with Chemotherapy
February 03, 2017 11:06 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 03, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc., (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that clinical results from the company’s open-label,...
Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers Symposium
January 20, 2017 17:05 ET
|
FibroGen, Inc.
SAN FRANCISCO, Jan. 20, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) today announced that updated results from an ongoing clinical study of pamrevlumab (FG-3019) in combination with...
FibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate Update
November 08, 2016 16:03 ET
|
FibroGen, Inc.
– Completes Enrollment of Roxadustat Phase 3 Studies in China for Anemia in CKD – – Conference Call and Webcast to be Held Today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific...
FibroGen to Report Second Quarter 2016 Financial Results on August 8, 2016
August 02, 2016 20:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...